At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 60 target
Drug / intervention
Brimonidine tartrate Gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Multicentric, Randomized, Double-blind, Placebo-controlled Study of TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis.
In Brief
A Phase 2 clinical trial evaluating Brimonidine tartrate Gel and Placebo gel (no Brimonidine tartrate) for EGFR Inhibitor-associated Rash. Currently recruiting, targeting 60 participants across 3 sites.
Detailed Summary
A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in metastatic colorectal cancer (mCRC) patients treated with monoclonal anti-EGFR antibodies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEGFR Inhibitor-associated Rash
CountriesFrance
Collaborators--
Timeline
Phase 2Recruiting
20252026
Enrollment StartJan 2025
First PostedFeb 2025
TodayJul 2026
Primary CompletionSep 2026
Study CompletionSep 2026
First PostedFeb 10, 2025
Enrollment StartJan 20, 2025
Primary CompletionSep 1, 2026
Study CompletionSep 30, 2026
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 1.4 years agoPrimary completion in 2 months
Interventions
Brimonidine tartrate Geldrug
Once daily applications for 7 days
Placebo gel (no Brimonidine tartrate)drug
Once daily applications for 7 days